JunHe Advises on Chifeng Gold’s Listing on the Main Board of the Hong Kong Stock Exchange
On March 10, 2025, Chifeng Jilong Gold Mining Co., Ltd. (“Chifeng Gold”) was listed on the main board of the Hong Kong Stock Exchange, with the stock code 6693. The listing of Chifeng Gold raised approximately HK$ 2.8 billion. Chifeng Gold is dedicated to the exploration, mining and processing of gold and other non-ferrous metals. …
JunHe Advises on Zhaojin Mining’s HKD 1.98 billion H-Share Placement
On March 31, 2025, Zhaojin Mining Industry Co., Ltd. (Zhaojin Mining, stock code: 1818.HK) announced the successful placement of 140 million H shares. The new H-shares were placed at an issue price of HKD 14.16 per share, raising approximately HKD 1.98 billion. This was the largest priced placement by a non-ferrous metals manufacturer on the …
Continue reading “JunHe Advises on Zhaojin Mining’s HKD 1.98 billion H-Share Placement”
JunHe Advises PegBio on their HKEX Listings
On May 27, 2025, PegBio Co., Ltd. (“PegBio”, the “Company” or the “Issuer”, stock code: 2565.HK) issued 19,283,500 ordinary shares and was listed on the main board of the Hong Kong Stock Exchange. PegBio is the first company to dismantle its red-chip structure and list under the Trial Measures for the Administration of Overseas Issuance …
Continue reading “JunHe Advises PegBio on their HKEX Listings”
JunHe Assists CM Bermuda in its Debt Restructuring and Sale of SPNT Shares
On December 30, 2024, CM Bermuda Limited (“CM Bermuda”) entered into an agreement with NYSE-listed SiriusPoint Ltd. (NYSE: SPNT), under which SiriusPoint would repurchase all ordinary shares and warrants held by CM Bermuda in SPNT for a total consideration of approximately USD 726 million. SiriusPoint would pay the amounts in two installments. The first installment …
Continue reading “JunHe Assists CM Bermuda in its Debt Restructuring and Sale of SPNT Shares”
JunHe Assists Dongying in the Court Approval of its Reorganization Plan
On October 24, 2024, the reorganization plan of Shanghai Dongying Real Estate Co., Ltd. (“Dongying”) was approved by the People’s Court of Pudong New Area of Shanghai Municipality. JunHe’s Shanghai office (“JunHe”) acted as the reorganization administrator and assisted Dongying in achieving an important milestone in the work of ensuring timely deliveries of presold homes. …
Continue reading “JunHe Assists Dongying in the Court Approval of its Reorganization Plan”
JunHe Assists Fibocom in Achieving Dual Primary Listings in A+H Markets through its HKEX Main Board Listing
On October 22, 2025, Shenzhen Fibocom Wireless Inc. (Fibocom, stock code: 0638.HK) issued 135,080,200 H shares (before exercising the over-allotment option) and was listed on the Main Board of the Hong Kong Stock Exchange. The issue price was HKD 21.50 per share, and the fundraising scale was approximately HKD 2.904 billion (before exercising the over-allotment …
JunHe Assists La Chapelle in Obtaining Court Approval for its Reorganization Plan after its A+H-Share Delisting and the Granting of a Whitewash Waiver by the SFC
On May 16, 2025, the reorganization plan of Xinjiang La Chapelle Fashion Co., Ltd. (‘La Chapelle’) was approved by the Shanghai Third Intermediate People’s Court (‘Shanghai Third Intermediate Court’). JunHe acted as the administrator, and partner Li Chenghao led JunHe’s team and acted as the principal. La Chapelle was established on March 14, 2001, and …
JunHe Assists Meituan in Its Largest Overseas Senior Bond Issuance
In November 2025, Meituan successfully completed a dual-currency bond issuance in US dollars and offshore RMB notes. The total issuance was USD 3 billion, including USD 600 million in 5.5-year bonds, USD 600 million in 7-year bonds, USD 800 million in 10-year bonds, RMB 2.08 billion in 5-year bonds and RMB 5 billion in 10-year …
Continue reading “JunHe Assists Meituan in Its Largest Overseas Senior Bond Issuance”
JunHe Assists Simcere Zaiming in a Strategic Partnership with NextCure Worth Over USD 700 million
On June 16, 2025, Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (HKEX: 2096), announced a strategic partnership with the U.S. biopharmaceutical company NextCure, Inc. (Nasdaq: NXTC). The partnership aims to jointly develop a novel antibody-drug conjugate (ADC) targeting CDH6, named SIM0505. The collaboration includes licensing NextCure to use Simcere Zaiming’s proprietary linker …
JunHe Assists TOP TOY in its Strategic Financing
JunHe recently served as the legal counsel to TOP TOY International Group Limited (TOP TOY) and assisted it in completing a strategic financing round led by Temasek. The post-money valuation of this financing stands at approximately HKD 10 billion, showcasing the market recognition of TOP TOY’s business model, brand equity and global expansion roadmap amidst …
Continue reading “JunHe Assists TOP TOY in its Strategic Financing”